

NHS Foundation Trust Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site** Date Site Rec **IRAS** Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay Second International Inter-Group Study for Classical Hodgkin's Lymphoma in 17/LO/1727 181571 30/04/2019 21/02/2019 18/01/2018 12/02/2019 26/02/2018 12/02/2019 12/03/2019 Neither Children and Adolescents A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent 2 18/LO/1290 249002 Cytomegalovirus (CMV) Vaccine, in CMV-Negative Recipient (R-) Patients 17/01/2019 06/11/2018 22/02/2019 23/04/2018 28/01/2019 05/02/2019 Neither Awaiting Kidney Transplantation from CMV-Positive Donors (D+) Phase 11, open-labelled, multi-centre, randomized controlled trial of Vinblastine 3 18/I O/0325 229140 +/- Bevacizumab for the treatment of chemotherapy-na?ve children with 04/05/2018 30/01/2019 26/04/2018 06/03/2019 13/03/2019 26/03/2019 Neither unresectable or progressive low grade glioma (LGG) A RandomizEd trial of ENtERal Glutamine to minimIZE thermal injury (The RE-17/YH/0013 213247 06/08/2019 19/06/2018 28/01/2019 27/04/2018 28/01/2019 19/02/2019 27/02/2019 Neither **ENERGIZE Study**) LUSTRUM cross-over cluster randomised controlled trial of Accelerated Partner 18/LO/0773 245000 Therapy (APT) to improve partner notification outcomes for heterosexual people 22/03/2019 27/07/2018 24/01/2019 23/07/2018 21/02/2019 21/02/2019 21/02/2019 with sexually transmitted Chlamydia trachomatis infection Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered 18/YH/0223 243476 16/09/2019 19/03/2018 05/02/2019 09/07/2018 02/04/2019 04/04/2019 07/05/2019 Neither Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care Multicentre, open label, prospective, single arm study of the safety and impact 235552 18/NE/0078 18/04/2019 27/07/2018 18/01/2019 13/04/2018 04/02/2019 15/02/2019 20/03/2019 Neither of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome Smart Matrix - Study Assessing the Safety and Performance of Smart Matrix? Dermal Replacement Scaffold in the Treatment of Full-8 18/WM/0143 245749 25/10/2019 26/06/2018 04/01/2019 15/08/2018 24/01/2019 05/02/2019 13/09/2019 Sponsor ThicknessWounds Arising From Surgical Excision of Basal Cell or SquamousCell Carcinomas in Male and Female Adult Patients A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study 18/EM/0229 250101 of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A 01/05/2019 19/07/2019 28/05/2018 13/03/2019 04/10/2018 22/03/2019 26/03/2019 Neither Nephropathy A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 10 18/LO/1522 249494 3 efficacy and safety study of OTO-104given as a single intratympanic injection 21/06/2018 18/02/2019 06/11/2018 18/02/2019 04/04/2019 09/04/2019 Neither in subjects with unilateral Meniere?s disease Chracterisation and targeted TReatment of ACute Exacerbations of Chronic 11 18/NW/0710 248241 Obstructive Pulmonary Disease. The TRACE-COPD Randomised Controlled 03/04/2019 19/03/2018 13/03/2019 21/11/2018 22/03/2019 22/03/2019 Trial.

Research & Innovation 1 of 14



			NI S TOURIGE								ation mast	
Sr	Rec Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Source of Reason for delay
12	2 18/NW/0742	236247	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas	14/05/2019	15/09/2017	27/02/2019	21/02/2019	15/03/2019	21/03/2019		16/04/2019	NHS Provider
13	18/YH/0055	241341	A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus- Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant	18/03/2019	09/08/2018	16/01/2019	10/05/2018	24/01/2019	28/01/2019		31/01/2019	
14	18/YH/0322	226765	SUNRRISE - Single Use Negative pRessure dressing for Reduction In Surgical site infection following Emergency laparotomy	19/01/2019	04/10/2018	02/01/2019	10/10/2018	02/01/2019	10/01/2019		15/01/2019	
15	18/WM/0327	252583	WORKWELL: A randomised controlled trial of job retention vocational rehabilitation for employed people with inflammatory arthritis: the WORKWELL trial.	12/03/2019	14/06/2018	21/01/2019	15/11/2018	22/01/2019	05/03/2019		07/03/2019	
16	5 18/LO/1922	251251	A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease	14/08/2019	11/07/2018	31/01/2019	09/01/2019	25/02/2019	04/03/2019		27/03/2019	Neither
17	19/NW/0026	249432	VX18-121-101: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older with Cystic Fibrosis	30/04/2019	13/12/2018	19/03/2019	12/03/2019	11/04/2019	12/04/2019		29/04/2019	
18	18/NW/0838	255084	Financial Incentives for Preventing Postpartum return to smoking: the FIPPS feasibility trial	01/04/2019	28/11/2018	17/01/2019	15/01/2019	17/01/2019	06/02/2019		06/02/2019	Neither
19	19/NW/0037	253482	Technical development of Automated Low Dose Risk Assessment Mammography (ALDRAM) in women attending for annual mammography through a family history clinic	28/03/2019	18/10/2018	05/02/2019	20/02/2019		26/03/2019		26/03/2019	
20	18/NW/0585	249119	A data collection and analysis pilot study to indicate preliminary characterisation of the electromyogram signal in relation to needle position with respect to the extraocular muscles, as observed during electromyogram needle guided treatment of strabismus in adults	21/02/2019	17/12/2018	09/01/2019	12/12/2018	17/01/2019	23/01/2019		23/01/2019	
21	18/NI/0240	258468	An Observational, Prospective Multicentre Clinical Study to assess the safety and clinical performance of a New Single-use Negative Pressure Wound Therapy System (PICO 7Y) for the Simultaneous Management of Bilateral Closed Incisions in Oncoplastic Breast Surgery Patients	01/03/2019	16/10/2018	17/01/2019	24/01/2019	14/02/2019	18/02/2019		18/02/2019	
22	2 18/WM/0204	244427	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation	15/04/2019	18/02/2019	11/03/2019	17/10/2018	12/03/2019	02/04/2019		12/04/2019	

Research & Innovation 2 of 14



NHS Foundation Trust Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site** Date Site Rec **IRAS** Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay Two-part, double-blind, placebo-controlled, randomized, parallel-group study: (Part 1) in healthy male subjects to assess safety and tolerability of ascending 242717 13/03/2019 23 18/NW/0098 repeated oral doses of BAY 1902607 including its effect on the 09/04/2019 13/03/2019 13/03/2019 10/05/2018 13/03/2019 13/03/2019 pharmacokinetics of a sub-therapeutic dose of midazolam (MDZ), followed by (Part 2) a two-way crossover administration of four different doses of BAY A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients 24 16/EE/0421 209972 11/12/2019 16/05/2016 14/01/2019 13/01/2017 14/02/2019 02/04/2019 12/02/2019 Sponsor with Open-Angle Glaucoma or Ocular Hypertension NEST: Clinical Evaluation of Daily Application of Nestorone? (NES) and 25 18/ES/0100 224226 14/03/2019 26/05/2016 18/01/2019 07/09/2018 18/01/2019 05/02/2019 06/02/2019 Testosterone (T) Combination Gel for Male Contraception CRYOSTAT-2: A multi-centre, randomised, controlled trial evaluating the 17/SC/0164 210735 26 effects of early high-dose cryoprecipitate in adult patients with major trauma 25/04/2019 30/08/2018 11/02/2019 26/05/2017 21/02/2019 22/02/2019 28/02/2019 Neither haemorrhage requiring major haemorrhage protocol (MHP) activation C-Stich2: Emergency Cervical Cerclage to Prevent Miscarriage and Preterm 239782 27 18/EM/0310 08/07/2019 03/01/2019 26/03/2019 16/11/2018 04/04/2019 16/04/2019 17/04/2019 Neither Birth: a Randomised Controlled Trial A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with 244842 09/10/2019 28 18/NW/0325 19/01/2018 21/03/2019 30/08/2018 13/05/2019 17/05/2019 26/09/2019 Sponsor Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy Patient-Reported Outcomes with the Accu-Chek? SoloMicropump System vs. 29 18/LO/1007 242697 03/07/2019 22/11/2017 10/06/2019 14/05/2019 14/06/2019 19/06/2019 19/06/2019 Insulet OmniPod? vs. Multiple DailyInjection Therapy in Type 1 Diabetes Cryoballoon Pulmonary Vein Isolation as First line treatment for Typical Atrial 30 18/NW/0074 236316 03/05/2019 15/10/2018 28/01/2019 28/02/2018 28/01/2019 05/02/2019 05/02/2019 Neither Flutter (CRAFT) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel 18/EM/0190 243165 28/03/2019 31 groupStudy to Investigate the Efficacy and Safety of CSL112in Subjects with 17/07/2019 18/04/2018 14/09/2018 25/04/2019 09/05/2019 02/07/2019 Sponsor Acute Coronary Syndrome An Extension Trial Evaluating the Long-term Safety and Efficacy of 32 18/YH/0265 249715 12/06/2019 03/07/2018 21/05/2019 24/08/2018 31/05/2019 06/06/2019 11/06/2019 Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism A Single-arm, Open-label, Multi-centre, Phase 1/II Study Evaluating the Safety and Clinical Activity of AUT03, a CAR T Cell Treatment Targeting CD 19 and 33 17/LO/0812 226255 14/05/2019 24/08/2018 16/04/2019 26/07/2017 18/04/2019 03/05/2019 10/05/2019 CD22 Followed by Consolidation with Anti PO I Antibody in Patients with

Research & Innovation 3 of 14

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)



Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site** Date Site Rec **IRAS** Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay Diagnostic performance of Smart Supra Perimetry (SSP) in comparison with 19/YH/0024 250459 34 20/06/2019 29/08/2018 06/06/2019 07/05/2019 11/06/2019 11/06/2019 11/06/2019 standard automated perimetry (SAP) and ocular coherence tomography (OCT A Prospective, Multicentre Clinical Trial Designed to Evaluate the Safety and 35 18/LO/0797 240879 Effectiveness of the XEN45 Glaucoma Treatment System in Patients with Angle 18/09/2019 03/09/2018 10/04/2019 02/10/2018 10/04/2019 17/04/2019 16/05/2019 Neither Closure Glaucoma Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A 36 17/WA/0192 227541 23/08/2019 06/09/2018 23/05/2019 12/11/2018 10/06/2019 17/06/2019 24/06/2019 Neither phase III multi-centre randomised controlled trial A preliminary study, evaluating and optimizing the clinical workflows to enable a 37 18/YH/0288 246234 03/05/2019 03/04/2019 20/09/2018 10/09/2018 01/05/2019 01/05/2019 01/05/2019 pilot RCT of 3-D printed dentures 38 18/EM/0426 236388 OPEN (Novel Outcome measures in PEripheral Nerve Injury) 01/07/2019 18/09/2018 16/05/2019 01/03/2019 16/05/2019 23/05/2019 23/05/2019 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THEEFFICACY AND SAFETY OF AG-348 IN 39 18/EM/0153 240773 09/10/2019 04/10/2018 29/04/2019 28/08/2018 23/05/2019 11/06/2019 29/08/2019 Sponsor NOTREGULARLY TRANSFUSED ADULT SUBJECTS WITHPYRUVATE KINASE DEFICIENCY Open label, two cohort (with and without imiglucerase), multicenter study to 18/SW/0218 232727 evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients 23/10/2018 29/05/2019 09/01/2019 08/07/2019 27/11/2019 Neither with Gaucher disease type 1 and type 3 AN OPEN-LABEL STUDY TO EVALUATE THEEFFICACY AND SAFETY OF 41 18/WM/0022 237623 AG-348 IN REGULARLYTRANSFUSED ADULT SUBJECTS WITH 02/10/2019 04/10/2018 03/05/2019 11/04/2018 23/05/2019 11/06/2019 22/07/2019 Sponsor PYRUVATE KINASE (PK) DEFICIENCY 42 17/LO/1819 210698 Image Directed Redesign of Bladder Cancer Treatment Pathways 12/06/2018 13/03/2019 04/12/2017 29/04/2019 17/05/2019 05/07/2019 Sponsor 43 19/YH/0050 249236 OpTIMUM: Optimising the Timing of whooping cough Immunisation in MUMs 16/08/2019 02/10/2018 10/06/2019 28/03/2019 11/07/2019 15/07/2019 16/07/2019 Role of Active Deresuscitation After Resuscitation-2 (RADAR-2): a phase 2 44 19/YH/0020 259869 14/06/2019 03/12/2018 15/03/2019 04/03/2019 01/05/2019 24/05/2019 29/05/2019 Sponsor randomised controlled trial.

Research & Innovation 4 of 14



Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site Date Site** Rec IRAS Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay A Phase 3b, Randomized, Double-blind, Placebo-controlledStudy to Evaluate 18/EM/0298 07/05/2019 45 251419 the Efficacy and Safety of TRC101 inDelaying Chronic Kidney Disease 04/09/2019 11/07/2018 21/11/2018 15/05/2019 17/05/2019 09/07/2019 Neither Progression in Subjectswith Metabolic Acidosis Alpha 2 agonists for sedation to produce better outcomes from critical illness 46 18/SS/0085 243640 (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, 25/10/2018 03/05/2019 12/11/2018 12/08/2019 28/05/2019 11/06/2019 05/08/2019 Sponsor open, phase 3 pragmatic clinical and cost- effectiveness trial with internal pilot An Open label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFN?) Monoclonal Antibody, and 47 18/NF/0328 238084 to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term 15/08/2019 21/03/2018 10/06/2019 06/12/2018 11/06/2019 01/07/2019 13/08/2019 Outcome in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis A double-blind, placebo controlled, randomized phase III trial to assess the 48 19/LO/0150 258058 safety and efficacy of Viaskin peanut in peanut-allergic young children 1-3 years 16/09/2019 26/11/2018 20/05/2019 08/03/2019 24/05/2019 07/06/2019 26/06/2019 Neither A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord?, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and 22/01/2019 49 18/SC/0395 245499 11/06/2019 07/05/2019 07/01/2019 13/05/2019 14/05/2019 16/05/2019 Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies VITALITY (GCA) A randomized, double-blind, placebo-controlled study to 50 19/EM/0016 253279 22/01/2019 11/06/2019 15/03/2019 04/07/2019 08/07/2019 29/07/2019 Neither evaluate the efficacy and safety of sarilumab in patients with giant cell artheritis A Randomized, Placebo-controlled, Double-blind, Phase 1/2a Study to Evaluate 51 19/SC/0031 257722 the Safety. Reactogenicity, and Immunogenicity of Ad26,RSV.preF in RSV-19/12/2018 23/05/2019 10/09/2019 11/06/2019 17/06/2019 18/06/2019 Neither seronegative Toddlers 12 to 24 Months of Age A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-52 19/EM/0047 257111 Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients 08/08/2019 05/12/2018 28/05/2019 04/04/2019 25/06/2019 27/06/2019 17/07/2019 Neither With Neovascular Age-Related Macular Degeneration (TENAYA) Investigation of the oral microbiome in pregnancy - do differences in oral 246813 21/05/2019 53 19/NW/0069 bacterial profiles and nitrate metabolism contribute to blood pressure regulation 06/06/2019 04/02/2019 26/04/2019 16/04/2019 21/05/2019 21/05/2019 in pregnant women? An open-label extension trial of the long-term safety of nintedanib in patients 54 18/EM/0365 252018 05/07/2019 23/08/2018 23/05/2019 15/01/2019 23/05/2019 28/05/2019 19/06/2019 with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) An open-label, pilot study to assess safety, tolerability, pharmacokinetics and 55 19/EE/0091 256412 effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus 29/11/2018 27/06/2019 20/05/2019 11/07/2019 12/07/2019 26/07/2019 Neither colonisation in lung transplant recipients

Research & Innovation 5 of 14



Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site** Date Site Rec IRAS Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay An open label phase IV, multicenter, international, interventional study to 245949 56 18/SC/0205 evaluate the effect of diet on gastrointestinal adverse events in patients with IPF 23/05/2019 15/01/2019 03/04/2019 23/05/2018 04/04/2019 26/04/2019 29/04/2019 treated with Pirfenidone A Phase II randomised, double blind, placebo-controlled, parallel group, multicentre study to evaluate the safety and efficacy of repeated oral doses of 57 18/NW/0565 246158 14/08/2019 13/09/2018 08/05/2019 30/01/2019 08/05/2019 05/06/2019 Neither 10/05/2019 Blautix in adult subjects with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D A feasibility Study of Prisms And Therapy In Attention Loss after stroke 58 18/YH/0480 232874 21/05/2019 19/10/2018 03/05/2019 09/01/2019 13/05/2019 13/05/2019 13/05/2019 (SPATIAL feasibility) An Open-Label, Adaptive Multiple-Dose Study To Investigate The Pharmacokinetics And Pharmacodynamics Of RO7234292 In CSF And 59 19/LO/0359 253287 20/08/2019 19/12/2018 24/06/2019 10/06/2019 12/07/2019 15/07/2019 15/07/2019 Plasma, And Safety And Tolerability Following Intrathecal Administration In Patients With Huntington?s Disease Randomised, double-blind, placebo controlled multi-centre study to assess the 60 18/NE/0023 230930 efficacy, tolerability and safety of Enterosgel in the treatment of Irritable Bowel 16/10/2019 14/03/2018 14/06/2019 27/02/2018 16/07/2019 17/07/2019 02/09/2019 Sponsor Syndrome with Diarrhoea (IBS-D) in adults When to Induce Labour to Limit risk in pregnancy hypertension? a multicentre, 61 18/LO/2033 252294 16/08/2019 11/01/2019 21/06/2019 10/01/2019 03/07/2019 03/07/2019 11/07/2019 randomised controlled trial ACCEPTABILITY STUDY ON KETOGENIC DIET SUPPLEMENT USING 18/WM/0312 228906 13/02/2019 13/04/2018 29/05/2019 17/12/2018 21/06/2019 24/06/2019 24/06/2019 CAMBROOKE KETOVIE? MEDICAL FOODS A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in 63 18/SW/0189 247797 23/11/2017 30/08/2019 11/10/2018 04/09/2019 27/09/2019 Sponsor Pediatric Patients (Age 12 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D) A randomised controlled trial of accelerated rehabilitation versus standard 19/WS/0008 231862 23/09/2019 23/09/2019 64 rehabilitation after double-row rotator cuff repair. Does rehabilitation regimen 18/10/2019 19/12/2018 21/08/2019 09/04/2019 23/09/2019 affect clinical outcomes? Telemedicine for adults with cochlear implants in the UK: empowering patients 65 18/SC/0658 242575 29/10/2019 25/07/2018 18/07/2019 28/11/2018 05/09/2019 06/09/2019 23/09/2019 Both to manage their own hearing healthcare. PITFALL - Randomised Open-Label Controlled Feasibility Trial of Probiotic in 66 18/NW/0863 257051 the elimination of faecal carriage Carbapenemase-bearing Klebsiella 13/08/2018 16/09/2019 02/04/2019 09/10/2019 09/10/2019 Neither pneumoniae.

Research & Innovation 6 of 14



Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site** Date Site Rec IRAS Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay 67 18/LO/1370 249657 PREcision Event Monitoring of PatienTs with Heart Failure usingHeartLogicTM 14/03/2019 08/08/2018 04/01/2019 27/07/2018 03/01/2019 15/01/2019 22/02/2019 Sponsor Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian 68 18/LO/0555 237992 18/11/2019 03/08/2018 24/07/2019 19/04/2018 24/09/2019 29/07/2019 30/07/2019 Neither Removal A randomized, multicentre, double-blind, placebo-controlled, phase-III clinical 69 18/I O/2136 251414 study to evaluate the efficacy and safety of intrathecally administered 20/08/2019 19/09/2018 26/07/2019 22/02/2019 31/07/2019 09/08/2019 09/08/2019 RO7234292 (RG6042) in patients with manifest Huntington?s Disease. ATLAS - A Randomized Open-label. Phase 1b Study of the Safety of 70 19/YH/0093 255567 Pirfenidone Solution for inhalation (AP01) in Patients with Idiopathic Pulmonary 14/11/2019 30/10/2018 13/08/2019 04/06/2019 16/08/2019 16/08/2019 07/10/2019 Sponsor **Fibrosis** CHIRON - An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety 71 18/LO/1435 247443 and Clinical Activity of Neoantigen Reactive T Cells in Patients with Advanced 01/02/2019 26/07/2019 25/04/2019 29/07/2019 30/07/2019 18/09/2019 Neither Non-Small Cell Lung Cancer Galapagos - A Phase 3, Randomized, double-blind, parallel-group, placebo controlled multicentre study to evaluate the efficacy and safety of two doses of 254823 72 19/SC/0034 10/10/2019 22/10/2018 17/07/2019 29/04/2019 19/07/2019 14/08/2019 14/08/2019 Neither GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis A Randomized, Double-Blind, Placebo Controlled, Global Phase 3 Study Of 73 19/EM/0003 251874 23/05/2019 04/01/2019 04/03/2019 20/02/2019 04/03/2019 08/04/2019 11/04/2019 Neither Edasalonexent In Pediatric Patients With Duchenne Muscular Dystrophy A study to evaluate safety, reactogenicity and immunogenicity of GSK 74 19/LO/0157 256597 Biologicals? RSV investigational vaccine based on viral proteins encoded by 11/09/2019 26/07/2018 18/07/2019 17/05/2019 01/08/2019 06/08/2019 12/08/2019 chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants Instantaneous wave-free ratio guided multi-vessel revascularization during 239022 25/10/2019 75 18/YH/0127 05/11/2018 07/08/2019 21/05/2018 20/09/2019 25/09/2019 26/09/2019 Sponsor percutaneous coronary intervention for acute myocardial infarction An open-label- study to assess the safety, pharmacokinetics and 76 18/ES/0124 248009 pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with 30/05/2019 05/11/2018 21/02/2019 19/12/2018 20/03/2019 11/04/2019 11/04/2019 Sponsor persistent pulmonary Aspergillus fumigatus infection. A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute 77 19/EM/0063 253607 16/12/2019 06/02/2019 16/08/2019 14/08/2019 11/09/2019 10/09/2019 14/10/2019 Neither Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation

Research & Innovation 7 of 14



Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site Date Site** Rec IRAS Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay 17/LO/0657 78 217991 IV iron for Treatment of Anaemia before Cardiac Surgery 24/10/2019 28/01/2019 11/07/2019 06/06/2017 29/07/2019 02/08/2019 06/09/2019 Sponsor Whole-body vibration training compared to muscle-strengthening exercises 79 19/NW/0249 258178 14/08/2019 19/02/2019 15/07/2019 08/07/2019 22/07/2019 22/07/2019 22/07/2019 alone in improving muscle function in children with Neurofibromatosis Type 1 A Phase 2b, multicentre, randomized, double-blind, placebo-controlled, parallel-80 18/WS/0199 253868 group study to evaluate the efficacy, safety, and tolerability of cenerimod in 08/02/2019 15/07/2019 17/12/2018 16/07/2019 02/08/2019 09/08/2019 Neither subjects with moderate to severe systemic lupus erythematosus (SLE) 81 18/SS/0140 252391 Epidemiological analysis for Hereditary Angioedema Disease (EHA Study) 07/10/2019 20/03/2019 06/09/2019 19/12/2018 11/09/2019 24/09/2019 30/09/2019 A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Itraconazole 12/10/2018 82 19/NW/0161 257243 09/10/2019 18/07/2019 15/04/2019 23/07/2019 16/08/2019 16/08/2019 Neither Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients with Allergic Bronchopulmonary Aspergillosis BiomArker-guided Duration of Antibiotic treatment in hospitalised PaTients with 17/SC/0434 209815 13/11/2019 83 16/01/2019 23/08/2019 23/10/2017 23/08/2019 24/09/2019 14/10/2019 Neither suspected Sepsis: the ADAPT-Sepsis Trial A Phase 3, Dose-Escalating Study in Children With Hyperkalaemia Between Birth and < 18 Years of Age to Evaluate Increasing Doses of Sodium Zirconium 84 19/EM/0014 251086 Cyclosilicate (SZC) Given Three Times Daily for the Correction of 26/06/2018 07/08/2019 19/03/2019 06/09/2019 10/09/2019 11/11/2019 Neither Hyperkalaemia and the Effectiveness of the Same Dose of SZC Given Once Daily to Maintain Normokalaemia Among Those Requiring Continuous Peanut Oral Immunotherapy Study of Early Intervention for Desensitization 85 19/YH/0097 261131 30/07/2019 04/04/2019 01/07/2019 28/05/2019 09/07/2019 11/07/2019 17/07/2019 (POSEIDON) Randomized, Double-Blind, Placeb-Controlled, Dose-ranging, Efficacy and 19/EM/0101 260487 86 Safety Study with Inhaled RVT-1601 for Treatment of Persistent Cough in 18/10/2019 14/01/2019 31/07/2019 20/05/2019 06/08/2019 08/08/2019 28/08/2019 Neither Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial ENCIRCLE Trial (Emergency Cerclage in Twin Pregnancies atImminent Risk of 87 17/EE/0040 222216 08/04/2019 09/08/2019 18/04/2017 16/08/2019 22/08/2019 29/08/2019 Neither Preterm Birth: an Open-Label RandomisedControlled Trial) A Randomised Controlled Trial of the impact on function of an unrestricted 88 19/NW/0250 192077 rehabilitation pathway of no precautions following total hip replacement 22/08/2019 09/05/2019 15/07/2019 10/06/2019 18/07/2019 01/08/2019 01/08/2019 (ReHip2)

Research & Innovation 8 of 14



Date Site **Date of First** HRA **Date Site** Non-Source of **Date Site Date Site** Date Site Rec **IRAS** Name of Trial **Participant** Confirmed Ready To **Approval** Confirmation Reason for Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay A multi-centre, primary care, randomised, parallel-group, superiority trial (with 247370 89 19/NW/0183 internal pilot) to evaluate the effectiveness of bracing in the management of 25/11/2019 01/05/2019 05/09/2019 19/06/2019 23/09/2019 24/09/2019 04/10/2019 Neither symptomatic knee osteoarthritis: the PROP OA trial Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C: A multinational 90 19/EM/0094 259038 19/11/2019 25/03/2019 30/08/2019 16/07/2019 02/09/2019 18/09/2019 17/09/2019 Neither multicenter, open-label, rater-blinded Phase II study. Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff 91 19/NW/0157 260774 25/03/2019 23/08/2019 12/07/2019 02/09/2019 17/09/2019 18/09/2019 Neither Disease): A multinational, multicenter, open-label, rater-blinded Phase II study. A Randomised, Double-blind, Placebo-Controlled, Crossover, Dose Escalation 92 19/NW/0181 260431 Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough 26/11/2019 27/03/2019 23/08/2019 14/06/2019 24/09/2019 27/09/2019 01/10/2019 Neither (RELIEF) Quality? Assured Follow-up of quiescent neovascular age-related macular 254025 93 18/LO/2111 22/10/2019 26/04/2019 30/07/2019 25/03/2019 06/08/2019 28/08/2019 23/09/2019 Sponsor degeneration by non-medical practitioners; a randomised controlled trial. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate 94 19/NE/0152 260824 the Impact of Evolocumab on Major Cardiovascular Events in Patients at High 08/02/2019 09/07/2019 18/06/2019 09/07/2019 05/08/2019 18/12/2019 Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Randomised controlled trial of an app-based digital intervention to support 95 18/LO/1674 244500 20/07/2019 07/12/2018 08/07/2019 16/11/2018 08/07/2019 08/07/2019 10/07/2019 breast cancer survivors prescribed hormone therapy (e-path study) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE-ASCENDING DOSE TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, 96 19/SC/0295 256518 AND PHARMACOKINETICS OF GWP42003-P IN CONJUNCTION WITH 07/06/2019 27/09/2019 14/08/2019 04/10/2019 08/10/2019 08/11/2019 Neither HYPOTHERMIA IN NEONATES WITH MODERATE OR SEVERE HYPOXIC ISCHEMIC ENCEPHALOPATHY Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): A randomised 97 18/SC/0624 244229 29/10/2019 18/02/2019 23/08/2019 23/09/2019 25/10/2019 21/12/2018 23/08/2019 Open Label Multi-Centre Clinical Trial A Post Market Prospective Study of FORTIVA? 1mm Porcine Dermis in Breast 98 19/NW/0281 261001 25/11/2019 12/12/2018 23/09/2019 23/09/2019 29/09/2019 30/09/2019 01/10/2019 Reconstruction (APPeaR) A Phase 3, Open-Label, Randomized, Parallel group study to evaluate the efficacy and safety of Intrapleural administration of adenovirus-delivered 99 18/SC/0635 248862 15/01/2018 20/09/2019 20/02/2019 24/09/2019 25/09/2019 11/10/2019 Neither interferon Alpha-2b (rAd-IFN) in combination with celecoxib and gemcitabine in patients with malignant pleural mesothelioma

Research & Innovation 9 of 14



			NI S TOUR								a c.on mast	
Sı	Rec Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Source of Reason for delay
10	0 18/WA/0108	235402	ICONS II: Identifying Continence OptioNs after Stroke randomised controlled trial		02/11/2018	11/06/2019	03/04/2018	12/09/2019	15/10/2019		17/12/2019	Sponsor
10	1 19/WA/0082	254478	Handling Oxygenation Targets in the Intensive Care Unit	06/12/2019	15/05/2019	12/08/2019	23/05/2019	10/09/2019	23/10/2019		24/10/2019	Sponsor
10	2 18/NW/0765	250220	Validating a device for the detection of bacteria and leukocytes in peritoneal effluent from patients with suspected peritonitis		21/08/2018	23/12/2019	01/04/2019	08/01/2020	15/01/2020			
10	3 18/LO/1289	245746	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma		20/09/2018	06/11/2019	05/09/2018	18/11/2019	20/11/2019		22/11/2019	
10	4 18/NW/0758	228234	The MAGIC trial (Melatonin for Anxiety Prior to General Anaesthesia In Children): A Randomised Controlled Trial of Melatonin Versus Midazolam in the Premedication of Anxious Children Attending for Elective Dental and ENT Surgery Under General Anaesthesia		14/11/2018	03/10/2019	16/01/2019	14/10/2019	31/10/2019		11/11/2019	NHS Provider
10	5 18/LO/1937	249639	A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	30/12/2019	29/10/2018	18/11/2019	01/03/2019	17/12/2019	20/12/2019		23/12/2019	
10	6 19/NW/0081	257593	An open-label, multi-centre, randomised, parallel design study to assess the efficacy of flash glucose monitoring in adults with type 1 diabetes		04/01/2019	14/11/2019	15/04/2019		18/11/2019		13/12/2019	
10	7 18/SC/0427	220853	The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study	13/11/2019	16/08/2018	03/10/2019	15/10/2018	03/10/2019	21/10/2019		21/10/2019	
10	B 19/LO/0408	257662	Percutaneous Deep Vein Arterialization	05/12/2019	08/11/2018	04/11/2019	03/05/2019	25/11/2019	27/11/2019		27/11/2019	
10	9 18/LO/2112	242027	BIOSOLVE-IV - BIOTRONIKS - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV	17/12/2019	16/11/2018	19/11/2019	21/06/2019	10/12/2019	12/12/2019			
11	0 17/LO/0801	225130	A Phase I/II, Open label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adenoassociated Viral Vector (FLT180a) in Patients With Haemophilia B		14/09/2018	12/11/2019	05/09/2017	10/12/2019	20/12/2019			

Research & Innovation 10 of 14



Sn	Rec Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Source of Reason for delay
111	19/NW/0070	247463	A Performance Evaluation of the LumiraDx Point of Care D-Dimer Assay		08/01/2019	31/10/2019	14/05/2019	02/12/2019	16/12/2019			
112	2 19/NW/0021	234848	BIOmarker-guided Treatment decisions In Psoriatic and Rheumatoid Arthritis (BIOTIPRA): A Feasibility Study	22/11/2019	05/02/2019	16/10/2019	24/01/2019	07/11/2019	08/11/2019		15/11/2019	
113	19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of BMS-986165 in Subjects with Lupus Nephritis on Background Treatment		26/04/2019	23/09/2019	17/06/2019	01/10/2019	06/11/2019		07/11/2019	Sponsor
114	18/LO/2070	246179	A feasibility trial of serial prophylactic exchange blood transfusion (SPEBT) in pregnant women with sickle cell disease (SCD) aiming to improve maternal and infant outcomes		30/11/2018	28/11/2019	28/03/2019	18/12/2019	24/12/2019		24/12/2019	
115	5 19/SC/0124	258913	A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin? in children with growth hormone deficiency		29/04/2019	18/10/2019	29/05/2019	07/11/2019	13/11/2019		14/11/2019	Neither
116	5 19/LO/0352	257478	A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies)		04/02/2019	04/11/2019	02/07/2019	13/11/2019	19/11/2019			
117	19/LO/0351	256743	A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy		28/06/2019	06/11/2019	03/07/2019	13/11/2019	19/11/2019		09/01/2020	
118	3 18/SC/0358	230456	Interleukin-2 Therapy of Autoimmunity in Diabetes		15/01/2019	09/12/2019	13/08/2018	15/01/2020	17/01/2020			
119	19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo- controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks		30/04/2019	09/10/2019	24/09/2019	01/11/2019	04/11/2019		12/12/2019	
120	19/SC/0312	263468	A reactogenicity, safety and immunogenicity study of GSK?s paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) GSK 143713A in immunocompromised paediatric renal transplant recipients.	18/11/2019	07/03/2019	09/10/2019	17/09/2019	04/11/2019	04/11/2019		08/11/2019	
121	18/NE/0073	234635	Heme arginate in transplantation study? a multi-centre blinded parallel-group randomised trial of heme arginate versus placebo to reduce delayed graft function in kidney transplant recipients.		01/04/2019	14/11/2019	11/12/2018	14/01/2020	16/01/2020			

Research & Innovation 11 of 14



										NH3 Foundation					
Sn	Rec Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Source of Reason for delay			
122	18/NI/0178	253727	A Phase 1 / 2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR mutation		04/07/2019	24/10/2019	29/07/2019	31/10/2019	14/11/2019		21/11/2019				
123	19/EM/0220	265213	A Phase III, randomized, multicenter, open-label, non-inferiority studyevaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	05/12/2019	04/04/2019	01/11/2019	11/09/2019	26/11/2019	28/11/2019		04/12/2019				
124	19/LO/1175	265529	A PHASE 1-2, SAFETY, TOLERABILITY AND PROOF OF CONCEPT STUDY OF A CRYOPRESERVED FORMULATION OF AUTOLOGOUS CD34+ HAEMATOPOIETIC STEM CELLS TRANSDUCED EX VIVO WITH CD11B LENTIVIRAL VECTOR ENCODING FOR HUMAN SGSH IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE IIIA (MPS IIIA. SANFILIPPO		08/05/2019	07/11/2019	25/10/2019	13/11/2019	05/12/2019		10/12/2019				
125	17/SC/0245	219967	A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301		04/06/2019	06/12/2019	30/06/2017	19/12/2019	03/01/2020		03/01/2020				
126	19/NW/0317	262846	A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment,Two Period Crossover Efficacy and Safety Study in Idiopathic PulmonaryFibrosis with Nalbuphine ER Tablets for the Treatment of CoughA3-		26/03/2019	23/10/2019	12/07/2019	29/10/2019	04/11/2019		04/11/2019				
127	18/EM/0079	230431	Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors: randomized placebo controlled trial		13/05/2019	01/11/2019	16/04/2018	08/11/2019	08/11/2019						
128	19/LO/0255	251219	A Multi-site randomised controlled trial assessing the effectiveness of the Little Journey app at reducing peri-operative anxiety compared to standard care.		10/06/2019	07/11/2019	08/05/2019	16/12/2019	20/12/2019						
129	19/NE/0195	264648	Open-label, randomized, two?arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)		03/06/2019	31/10/2019	13/08/2019	15/11/2019	19/11/2019		22/11/2019				
130	19/NS/0060	264064	Ticagrelor CytoSorb? Hemoadsorption (TISORB): Prospective, Open, Multicenter, Single-arm Study to Demonstrate the Feasibility of the CytoSorb? 300 mL Device to Remove Ticagrelor During Cardiopulmonary Bypass in Patients on Ticagrelor Undergoing Emergent Cardiothoracic Surgery		13/06/2019	15/11/2019	13/06/2019	02/12/2019	12/12/2019		13/01/2020				
131	19/EM/0248	265942	A Phase 4, Open-label, Single Arm Study to Evaluate the Safety andTolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Paediatric Participants Receiving Emetogenic Chemotherapy		08/07/2019	01/11/2019	09/10/2019	13/12/2019	16/12/2019		07/01/2020				
132	19/LO/1318	268820	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)		05/07/2019	04/11/2019	29/10/2019	04/11/2019	28/11/2019		06/12/2019				

Research & Innovation 12 of 14



Date Site Source of **Date of First** HRA **Date Site** Non-**Date Site Date Site Date Site** Rec IRAS Name of Trial **Participant Approval** Confirmed Ready To Reason for Confirmation Reference Invited Selected Confirmed Recruited Date By Sponsor Status Start delay An overarching study for children and adults with Frontline and Relapsed 19/NE/0145 133 254931 07/11/2019 27/11/2019 02/12/2019 22/07/2019 22/07/2019 RhabdoMvoSarcoma. Comparison of pressure measurements in water filled and air charged catheters 134 18/NI/0160 243319 15/05/2019 16/10/2019 17/10/2018 05/12/2019 05/12/2019 Sponsor during urodynamic studies Does improved ability to achieve single leg stance (SLS) lead to a more efficient 135 19/NW/0621 257294 09/09/2019 18/12/2019 17/12/2019 23/12/2019 23/12/2019 gait pattern in adults with acquired brain injury (ABI)? REACH-ASD Trial: A Randomised Controlled Trial of Psycho-Education and 136 19/NW/0596 268914 Acceptance & Commitment Therapy for Parents of Children recently diagnosed 01/08/2019 06/12/2019 22/11/2019 12/12/2019 12/12/2019 with ASD A randomized, treatment open-label, dose-blinded parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 137 19/NW/0570 234906 08/07/2019 13/11/2019 28/10/2019 21/11/2019 27/11/2019 13/01/2020 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy A Phase 2, Multicenter, Multinational, OpenLabel, DoseEscalationStudy to Evaluate the Safety and Efficacy of ALXN1101 in Pediatric Patients with 14/WS/0052 141441 138 Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated with 22/07/2019 05/12/2019 12/11/2019 12/12/2019 18/12/2019 Recombinant Escherichia coliderived Cyclic Pyranopterin Monophosphate (rcPMP) A comparison of non-linear frequency compression and conventional 139 19/WS/0162 264352 processing in adult patients with and without dead regions who have a 20/11/2019 08/10/2019 04/11/2019 04/11/2019 05/11/2019 05/11/2019 moderate to severe sensorineural hearing loss. A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to 140 19/SC/0416 269256 Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended 20/08/2019 31/10/2019 09/10/2019 04/11/2019 05/11/2019 19/11/2019 Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY) Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A 269017 30/09/2019 15/11/2019 22/11/2019 25/11/2019 141 19/NW/0490 09/08/2019 12/11/2019 or B with inhibitors PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A 142 19/LO/0717 262991 Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy 30/08/2019 12/12/2019 10/06/2019 13/01/2020 15/01/2020 and Safety of Pegzilarginase in Children and Adults with Arginase 1 Deficiency An open-label, multi-centre, randomised, two-period, crossoverstudy to assess the efficacy, safety and utility of day and nightautomated closed-loop glucose 143 13/EE/0321 136248 control under free livingconditions compared to conventional insulin pump 20/11/2019 30/10/2018 25/10/2019 06/07/2019 07/11/2019 08/11/2019 13/11/2019 therapycombined with continuous glucose monitoring in adults withtype 1 diabetes and HbA1c between 7.5% and 10% (phase 1) and HbA1c below 7.5%

Research & Innovation 13 of 14



;	Sn	Rec Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Source of Reason for delay
1	44	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	21/11/2019	04/06/2019	09/10/2019	26/07/2019	24/10/2019	04/11/2019		18/11/2019	
1	45	19/NW/0285	235419	A European Multicenter Study on the Effect of Lipopro-tein(a) Elimination by Lipoprotein Apheresis on Cardiovas-cular outcomes		08/05/2019	01/11/2019	27/09/2019		19/11/2019		19/11/2019	
1	46	17/NW/0394	225510	An open-label, multi-centre, randomised, two-period, crossover study to assess the efficacy, safety and utility of 16 week day and night automated closed-loop glucose control combined with pump suspend feature under free living conditions compared to sensor augmented insulin pump therapy in older adults with type 1 diabetes	06/11/2019	21/11/2016	07/10/2019	08/08/2019	02/09/2019	18/10/2019		31/10/2019	

Research & Innovation 14 of 14